Companion diagnostic

Predicine to Present 15 Liquid Biopsy Studies at AACR 2024

Retrieved on: 
Friday, April 5, 2024
CDX, Liquid biopsy, Companion diagnostic, AACR, Drug resistance, Medical imaging

HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc. A leading precision oncology company, announced today that it will present data from 15 ctDNA studies at AACR 2024, spotlighting the clinical utility of Predicine’s genomic and epigenomic liquid biopsy solutions for patient selection, disease monitoring, and disease mechanism studies.

Key Points: 
  • HAYWARD, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc. A leading precision oncology company, announced today that it will present data from 15 ctDNA studies at AACR 2024, spotlighting the clinical utility of Predicine’s genomic and epigenomic liquid biopsy solutions for patient selection, disease monitoring, and disease mechanism studies.
  • The forthcoming data represents significant potential for the practical application of Predicine’s cutting-edge liquid biopsy technology in personalized cancer care, clinical trials and Companion Diagnostic (CDx) advancement.
  • Numerous studies to be unveiled at the conference emphasize the distinct advantages of personalized PredicineBEACON™ and methylation-based PredicineALERT™ MRD underscoring the clinical utility of Predicine’s complete range of liquid biopsy solutions in biomarker discovery, therapy selection, response monitoring and drug resistance mechanism analyses.

Companion Diagnostic Markets Transforming the Diagnostics Industry: In-Depth Analysis and Future Forecast (2023-2027) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 27, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Research, Companion diagnostic, Organization, Application, Consultant, Hospital, SRL Diagnostics, Laboratory, Diagnosis, Future, FDA, Medical device

The "Companion Diagnostic Markets - the Future of Diagnostics by Application, Technology and Funding With Executive and Consultant Guides 2023-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Companion Diagnostic Markets - the Future of Diagnostics by Application, Technology and Funding With Executive and Consultant Guides 2023-2027" report has been added to ResearchAndMarkets.com's offering.
  • The diagnostics industry is undergoing a significant transformation with the rapid advancement of Companion Diagnostics, especially within oncology, a sector witnessing the adoption of immune-oncology practices.
  • Research on Personalized Companion Diagnostics indicates a trend toward customization in patient care, significantly impacting the future of diagnostics.
  • The future of diagnostics heralds a period of innovative, tailored solutions that elevate patient care to new heights.

Seneca Therapeutics Announces Publication of TEM8 Review Article “TEM8 in Oncogenesis” in Cells Journal

Retrieved on: 
Wednesday, November 15, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Companion diagnostic, Clinical trial, ANTXR1, Neoplasm, Patient, Publication, Therapy, University, University of Miami, FDA, Medical device, Medical imaging, Cell

Seneca Therapeutics, Inc., announced today the publication of “TEM8 in Oncogenesis” in Cells.

Key Points: 
  • Seneca Therapeutics, Inc., announced today the publication of “TEM8 in Oncogenesis” in Cells.
  • The authors are Dr. Samuel Kareff and Dr. Aman Chauhan from Sylvester Cancer at University of Miami, Dr. Virginia Corbett from Mt.
  • Sinai Tisch Cancer Center and Dr. Paul Hallenbeck from Seneca Therapeutics.
  • “This review article provides an excellent update on both TEM8, ANTXR1 - the gene that encodes TEM8 - and SVV-001 which targets TEM8.

BioAI Health Welcomes Jill Stefanelli, PhD, As Latest Addition to Seasoned Advisory Board

Retrieved on: 
Wednesday, March 22, 2023
Pacific Biosciences, Senior, U.S. Department of Defense Strategy for Operating in Cyberspace, Sickle Cell Anemia, a Molecular Disease, Biotechnology, Stefanelli, Atlas, Health, Personalized medicine, Cancer, Lung cancer, Multimedia, Thermo Fisher Scientific, Companion diagnostic, Doctor of Philosophy, U.S. Department of Agriculture Cotton Annex, Acquisition, USDA, Roche, Medicine, ISCB Senior Scientist Award, AI, Partnership, Pharmaceutical industry, Management, Plum Island (New York)

MANCHESTER, N.H., March 22, 2023 /PRNewswire/ -- BioAI Health, an emerging leader in the development of AI/SciML-driven predictive testing to improve cancer treatment and outcomes, today announced the appointment of Jill Stefanelli, PhD, as newest member to its growing advisory board of seasoned industry professionals. In this position, Dr. Stefanelli will help drive commercial and corporate strategy for the company.

Key Points: 
  • "I am very excited to join BioAI's world-class advisory board and drive corporate development," said Dr. Stefanelli.
  • Jill has a proven track record in building Precision Medicine businesses and expertise in commercializing novel technologies for clinical development and diagnostics.
  • "Our team is extremely excited to have Jill onboard and have her lead BioAI's strategic initiatives Lung Panel Consortium & Data Insights Atlas RWE platform," said Thomas Colarusso, CEO and Cofounder at BioAI Health.
  • BioAI Health is a leading provider of multimodal AI for digital health in precision medicine.

DGAP-News: Aignostics Raises €14m Series A to Advance AI-powered Pathology

Retrieved on: 
Thursday, September 15, 2022
Immunohistochemistry, H&E, Marie Cassidy, Acceleration, Cdx, Companion diagnostic, Machine learning, BIH, Biomarker, Berlin Institute for Population and Development, MIF, Company, Growth, IHC, Cros, VC, Patient, Clinical trial, Investment, CEO, Technology, Wellington Partners, Â, CTO, Solution, Pathology, Metadata, Diagnosis, Pharmacy, Digital health, Research, AI, GCP, Medical device, Medical imaging, Pharmaceutical industry, Fine chemical, Technical University of Berlin

Recognizing that, Aignostics focuses on building leading AI models for the detailed analysis of tissue samples and associated metadata for its blue-chip pharma and biotech clients.

Key Points: 
  • Recognizing that, Aignostics focuses on building leading AI models for the detailed analysis of tissue samples and associated metadata for its blue-chip pharma and biotech clients.
  • Aignostics AI models go well beyond current off-the-shelf solutions and established approaches.
  • Dr. Rainer Strohmenger, Managing Partner at Wellington Partners commented: We are deeply impressed by the Aignostics team and technology.
  • To date, Aignostics has raised close to 20m in funding from leading VC investors and has offices in Berlin, Germany, and Boston, U.S.

Aignostics Raises €14m Series A to Advance AI-powered Pathology

Retrieved on: 
Thursday, September 15, 2022
Immunohistochemistry, H&E, Marie Cassidy, Acceleration, Cdx, Companion diagnostic, Machine learning, BIH, Biomarker, Berlin Institute for Population and Development, MIF, Company, Growth, IHC, Cros, VC, Patient, Clinical trial, Investment, CEO, Technology, Wellington Partners, Â, CTO, Solution, Pathology, Metadata, Diagnosis, Pharmacy, Digital health, Research, GLOBE, AI, GCP, Medical device, Medical imaging, Pharmaceutical industry, Fine chemical, Technical University of Berlin

Recognizing that, Aignostics focuses on building leading AI models for the detailed analysis of tissue samples and associated metadata for its blue-chip pharma and biotech clients.

Key Points: 
  • Recognizing that, Aignostics focuses on building leading AI models for the detailed analysis of tissue samples and associated metadata for its blue-chip pharma and biotech clients.
  • Aignostics AI models go well beyond current off-the-shelf solutions and established approaches.
  • Dr. Rainer Strohmenger, Managing Partner at Wellington Partners commented: We are deeply impressed by the Aignostics team and technology.
  • To date, Aignostics has raised close to 20m in funding from leading VC investors and has offices in Berlin, Germany, and Boston, U.S.

Alphageneron to Participate in Cell Therapy Durability Response Summit

Retrieved on: 
Wednesday, August 17, 2022
Woman, JD, CAR, Cell, GLOBE, Standard of care, Cancer, American Society of Clinical Oncology, Antibody-drug conjugate, Toxicity, Clinical trial, NK, Potency (pharmacology), Lung cancer, NSCLC, Man, Endpoint security, Patient, CBR, Companion diagnostic, Large-cell lung carcinoma, Company, Control, Partial-response maximum-likelihood, Safety, SOC, Treatment of lung cancer, Intention-to-treat analysis, Private Securities Litigation Reform Act, CR, Liquid biopsy, Engagers, Exosome, Disease, Pharmaceutical industry, Vaccine

CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (Alphageneron or the Company), a clinical stage pharmaceutical company developing a diverse platform of cell and antibody-based therapeutic candidates to treat cancer, announced today that their Chief Executive Officer, Robert K. Brooks, JD, will participate in the Cell Therapy Durability Response Summit that will be held August 22-23, 2022.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Alphageneron Pharmaceuticals, Inc. (Alphageneron or the Company), a clinical stage pharmaceutical company developing a diverse platform of cell and antibody-based therapeutic candidates to treat cancer, announced today that their Chief Executive Officer, Robert K. Brooks, JD, will participate in the Cell Therapy Durability Response Summit that will be held August 22-23, 2022.
  • Membrane Hsp70 (mHsp70) is a cancer biomarker, highly expressed on the cellular membrane of a wide range of cancers, not on normal cells.
  • ENKASTIM is an autologous cell therapy that activates the patients NK cells to kill cancer cells.
  • A prior Phase IIa (randomized, controlled) clinical trial involving fourteen (14) patients with advanced (Stage IIIb) inoperable NSCLC was conducted.

PreventionGenetics Receives FDA Approval for its Companion Diagnostic Genetic Test as a Class II Medical Device

Retrieved on: 
Thursday, June 30, 2022
LEPR, FDA, Patient, Arousal, Lists of diseases, Benzyl alcohol, Suicidal ideation, Abdominal pain, Adult, FDA Center for Devices and Radiological Health, Skin, CDRH, Device, Risk, Vomiting, Genetic testing, VUS, Depression, Obesity, Prevalence, Proopiomelanocortin, Cdx, PCSK1, BBS, Food, Sexual arousal, Headache, Center, Companion diagnostic, Pigment, FACMG, Alström syndrome, Incidence, Diarrhea, Food and Drug Administration Amendments Act of 2007, Physician, Pregnancy, Nausea, Fetus, Medical device, Vaccine, Birth control, Pharmaceutical industry, POMC, Doctor of Philosophy

MARSHFIELD, Wis., June 30, 2022 /PRNewswire/ -- PreventionGenetics, a subsidiary of Exact Sciences Corp., announced today that it was recently granted marketing authorization for the POMC/PCSK1/LEPR companion diagnostic (CDx) genetic test as a Class II device by the Center for Devices and Radiological Health (CDRH), a division of the Food and Drug Administration (FDA). PreventionGenetics, an accredited germline DNA testing laboratory offering genetic testing to patients and physicians around the world, developed the test in collaboration with Rhythm Pharmaceuticals, Inc.

Key Points: 
  • PreventionGenetics, an accredited germline DNA testing laboratory offering genetic testing to patients and physicians around the world, developed the test in collaboration with Rhythm Pharmaceuticals, Inc.
  • The POMC/PCSK1/LEPR companion diagnostic (CDx) genetic test is for in vitro diagnostic use only and must be ordered by a qualified professional in accordance with clinical laboratory regulations.
  • For more information on PreventionGenetics and the Companion Diagnostic test, visit https://www.preventiongenetics.com/sponsoredTesting/Rhythm/CDX .
  • To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at 833-789-6337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Leap Therapeutics Reports First Quarter 2022 Financial Results

Retrieved on: 
Friday, May 13, 2022
Company, Risk, Private Securities Litigation Reform Act, Research, Docetaxel, Survival, EDGAR, Nasdaq, Medicare Part D, Progression-free survival, Patient, Tislelizumab, Therapy, ORR, Clinical trial, Stomach, COVID-19, Myeloid-derived suppressor cell, Great Leap Forward, Cancer, Prostate cancer, Companion diagnostic, PFS, Securities Exchange Act of 1934, Securities Act of 1933, DKK1, NK, NYU Langone Health, ASCO, Drug Quality and Security Act, Leica Biosystems, Leica, Distinguishing, Growth, Outline, Annual report, Pharmaceutical industry, Medical imaging, Cryptocurrency, Part, LEAP, BeiGene, New York University

CAMBRIDGE, Mass., May 13, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter endedMarch 31, 2022.

Key Points: 
  • CAMBRIDGE, Mass., May 13, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter endedMarch 31, 2022.
  • Net Loss was$10.4 millionfor the first quarter 2022, compared to$9.1 millionfor the same period in 2021.
  • Research and development expenses were $7.8 millionfor the first quarter 2022, compared to$6.8 millionfor the same period in 2021.
  • General and administrative expenses were$2.8 millionfor the first quarter 2022, compared to$2.7 millionfor the same period in 2021.

Paige Announces Executive Leadership Appointments

Retrieved on: 
Wednesday, January 12, 2022
Oncology, Data Management, Medical Devices, Health, Technology, Software, Marie Cassidy, Doctor of Philosophy, Patient, Technology, Companion diagnostic, IVD, Roche Diagnostics, U.S. Department of Defense Strategy for Operating in Cyberspace, Memorial Sloan Kettering Cancer Center, Partnership, Senior, Growth, Oncology, CEO, Digital, Pacific Biosciences, Health, Cancer, Acquisition, Invitae, ISCB Senior Scientist Award, Industry, Drug development, Jim Breyer, McKesson Corporation, AI, Pathology, MSK, FDA, Lung cancer, Thermo Fisher Scientific, Laboratory, Workflow, Lead, Head, Board, Commercial Operating System (COS), Management, Medical device

We are excited to welcome Andy and Jill into their new roles on the executive leadership team, said Kenan Turnacioglu, Ph.D., Chair of the Board of Directors at Paige.

Key Points: 
  • We are excited to welcome Andy and Jill into their new roles on the executive leadership team, said Kenan Turnacioglu, Ph.D., Chair of the Board of Directors at Paige.
  • Their leadership experience and know-how across the diagnostics and life science industries will be instrumental as Paige looks to expand its business in building technology that can ultimately save lives.
  • The leadership appointments build upon a year of record growth for Paige.
  • We are confident that they will propel Paige to new heights and look forward to working closely with them as Paige advances its world-class AI technology to address cancers and other applications.